Mitral re-valve-in-valve as a new perspective for high-risk patients with prosthetic valve dysfunction: case reports.
Matheus Ramos Dal PiazLucas Tachotti PiresJonathan Cayo Urdiales HerreraAndré Luis Bezerra LabatFelipe Reale CividanesGuilherme Sobreira SpinaJosé Honório de Almeida Palma da FonsecaFlávio TarasoutchiPublished in: European heart journal. Case reports (2023)
Valve-in-valve transcatheter mitral valve implantation was approved in 2017, and, since then, it has been used in several countries, mainly in high-risk patients. Nevertheless, these prosthetic valves may complicate with stenosis or regurgitation, demanding reinterventions. Although there are favourable data for mitral ViV, re-ViV still lacks robust data to support its performance, with only case reports in the literature so far. It is possible that in high-risk patients, there is a greater benefit from re-ViV when compared with the surgical strategy. However, this hypothesis must be studied in future controlled trials.
Keyphrases
- mitral valve
- aortic stenosis
- aortic valve
- ejection fraction
- left atrial
- left ventricular
- end stage renal disease
- aortic valve replacement
- transcatheter aortic valve replacement
- newly diagnosed
- chronic kidney disease
- systematic review
- oxidative stress
- electronic health record
- patient reported outcomes
- coronary artery disease
- machine learning